Dow Inc. stock underperforms Wednesday when compared to competitorsWhy Gamers Need to Watch Arm’s Share Price: It Could Shape the Future of Gaming
India is set to significantly expand its presence in the global medical technology (MedTech) industry, increasing its market share from the current 1.6 to 10-12 per cent over the next 25 years, according to a report by EY India. The report noted that this growth aligns with the rapid development of the country's MedTech sector, which is projected to reach new heights in the coming decades. The Indian medical device market, valued at approximately USD 12 billion in 2023-24, is anticipated to grow more than four-fold to USD 50 billion by 2030. It said "the (Indian) market ranks among the top 20 countries globally, with a market share of 1.65 per cent This share is expected to rise between 10 per cent and 12 per cent within the next 25 years". The report mentioned that India's transition from a significant importer to a potential global leader and exporter in the MedTech industry will be driven by its strategic strengths. These include a skilled workforce, cost advantages, technological advancements, and government initiatives that encourage domestic manufacturing and innovation. Together, these factors position India to not only participate but lead the future direction of the global MedTech market. Design Microsoft Designer Guide: The Ultimate AI Design Tool By - Prince Patni, Software Developer (BI, Data Science) View Program Finance Crypto & NFT Mastery: From Basics to Advanced By - CA Raj K Agrawal, Chartered Accountant View Program Office Productivity Microsoft Word Mastery: From Beginner to Expert By - CA Raj K Agrawal, Chartered Accountant View Program Office Productivity Excel Essentials to Expert: Your Complete Guide By - Study At Home, Quality Education Anytime, Anywhere View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Tally Prime & GST Accounting: Complete Guide By - CA Raj K Agrawal, Chartered Accountant View Program Artificial Intelligence(AI) Learn InVideo AI: Create Videos from Text Easily By - Prince Patni, Software Developer (BI, Data Science) View Program Entrepreneurship Validating Your Startup Idea: Steps to Ensure Market Fit By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Entrepreneurship Crafting a Powerful Startup Value Proposition By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Finance Value and Valuation Masterclass By - CA Himanshu Jain, Ex McKinsey, Moody's, and PwC, Co - founder, The WallStreet School View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program Legal Complete Guide to AI Governance and Compliance By - Prince Patni, Software Developer (BI, Data Science) View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Web Development Django & PostgreSQL Mastery: Build Professional Web Applications By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrow's Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Leadership Business Storytelling Masterclass By - Ameen Haque, Founder of Storywallahs View Program The report added "India stands on the cusp of redefining its role in the international MedTech arena, not merely as a market participant but as a frontrunner steering the industry's future direction". Key drivers for this growth include the rising prevalence of chronic diseases, a growing elderly population, and an increasing focus on preventive healthcare. Additionally, there is a shift toward digitally integrated healthcare systems, next-generation therapies, and care settings outside traditional hospitals. The expanding middle class, rising incomes, and greater penetration of healthcare insurance are also contributing factors. The report also highlighted that India's inherent strength in digital and technological innovation is another major asset. Combined with growing infrastructure, increased medical tourism, and a strong push from the government, the MedTech industry is set for a transformative journey. "While India is currently a significant importer of medical devices, it has the potential to emerge as a key exporter and a global MedTech industry leader" the report said. With these developments, India stands poised to redefine its role in the global MedTech landscape, emerging as a frontrunner in driving innovation and reshaping healthcare delivery worldwide. Nominations for ET MSME Awards are now open. The last day to apply is December 15, 2024. Click here to submit your entry for any one or more of the 22 categories and stand a chance to win a prestigious award. (You can now subscribe to our Economic Times WhatsApp channel )Iconic Portofino Tower Condominium Hits the Market listed by Bo Palazola
Technology and TV writer Thank you for signing up! Did you know with an ad-lite subscription to Bedford Today, you get 70% fewer ads while viewing the news that matters to you. ITV gave the stars of I’m a Celebrity a reprieve tonight (December 4) as no eviction took place. Instead they started the first part of a competition for a major advantage. A golden ticket straight to the iconic Celebrity Cyclone was up for grabs - and it includes safety from two evictions. All they had to do was compete in the gruelling Arcade of Agony. Advertisement Advertisement Fans will have to wait until Thursday’s (December 5) episode to find out who has won the major advantage. Here’s all you need to know: Instead of a public vote, the celebrities were split into two groups and challenged with competing to win a golden ticket to the Celebrity Cyclone on the weekend. Four celebs took on the Arcade of Agony first, before the remaining cast had their turn. The celebrities will be safe until the conclusion of the golden ticket challenge on Thursday (December 5). Ant and Dec will announce when the public vote has opened again. Melvin Odoom is the most recent star to be sent home from the jungle . He was evicted on Tuesday (December 3) after the latest public vote - and was visibly relieved at being able to go home. Before that Tulisa, Dean and Jane were evicted in the first three public votes. What do you think of this year’s I’m a Celebrity cast - is it one of the best? Share your thoughts by emailing me: [email protected] . Comment Guidelines National World encourages reader discussion on our stories. User feedback, insights and back-and-forth exchanges add a rich layer of context to reporting. Please review our Community Guidelines before commenting.
None
Significant investment flows are coming from XRP’s positive momentum driven by regulatory clarity rumors and RXS’s creative use case in real-world asset tokenizing. With clear paths for their expansion, analysts and crypto enthusiasts both believe XRP and RXS will rocket past the $5 mark. Here’s the timeline. Ripple (XRP): The Road to $5 Thanks to recent speculation on SEC chief Gary Gensler’s possible resignation, XRP has been riding a wave of good sentiment, headed toward $5. For many who see this revelation as a means of addressing regulatory issues impeding XRP’s expansion, it has inspired hope. XRP is $1.12 as of right now, a 66.27% increase over the previous week and a doubling in value over the past 30 days. The price increase of XRP has been mostly driven by institutional investors’ fresh curiosity. Accumulating XRP at a fast speed, big investors hope for even more positive momentum. This build-up fits forecasts from analysts projecting XRP’s price to rise above $5 by 2025. Regulatory clarity, more acceptance, and a positive market attitude are the main elements influencing XRP’s possible expansion. Investor confidence has been greatly increased by the settlement of Ripple’s legal dispute with the SEC earlier this year, and any additional regulatory actions could improve XRP’s standing. Furthermore becoming rather popular are Ripple’s payment options, especially for cross-border transactions, drawing more institutional users to the XRP Ledger. Major altcoins like XRP are gaining from the good momentum as the larger crypto market gets into a bull run. One of the most likely cryptocurrencies for the rest of 2024 and into 2025, analysts think XRP might hit $5 if regulatory obstacles are removed and adoption keeps increasing. Rexas Finance (RXS): The Revolutionary Token Set to Rocket Past $5 Institutional adoption is helping XRP, but Rexas Finance (RXS) is forging forward as a ground-breaking platform that connects the digital and real worlds. Real-world assets like gold, fine art, and real estate can be tokenized, purchased, sold, and held in fractional ownership by users of Rexas Finance. RXS is now a unique token in the quickly expanding real-world asset (RWA) market thanks to this creative use case. With a presale price of just $0.08 as of writing, Rexas Finance has shown tremendous promise. Over $10.6 million has already been raised during the presale, indicating high investor interest. Investor confidence has increased as a result of Certik’s platform assessment, which guarantees security and transparency. The $1 million giveaway campaign, which has received over 249,000 entries and intends to award 20 winners with $50,000 worth of RXS each, has helped RXS’s presale momentum. In addition to raising awareness, this effort has drawn in a wide variety of investors. Because of its distinctive value offer and increasing investor interest, Rexas Finance (RXS) has a good chance of surpassing $5. The platform’s capacity to tokenize almost any valuable asset creates a huge unexplored market and puts RXS in a position to promote broad adoption. Experts believe that the token’s final listing price will exceed $0.20, paving the way for exponential growth following the launch. The presale’s performance, with each stage selling out faster than anticipated, indicates significant demand. Furthermore, large investors are beginning to see RXS as a high-growth prospect; forecasts indicate that it could rise to $5 as early as Q1 2025. To differentiate itself in the cryptocurrency market, Rexas Finance incorporates blockchain technology with practical applications. RXS may experience a large price increase, according to analysts, driven by its usefulness and expanding use, perhaps providing early investors with returns of up to 6,000% in a year. Conclusion Two of the most interesting investment prospects in the present crypto industry are Ripple (XRP) and Rexas Finance (RXS). With a $5 aim by the end of 2025, XRP is a solid option for continuous development given its regulatory development and usefulness in cross-border payments. However, Rexas Finance’s cutting-edge real-world asset tokenization technology is expected to upend established markets and reach $5 as early as Q1 2025. These two tokens are definitely worth taking into consideration for investors looking for high-growth prospects. Both are poised for exponential growth in the upcoming months as RXS transforms asset ownership and XRP establishes its place in institutional finance. For more information about Rexas Finance (RXS) visit the links below: Website: https://rexas.com Win $1 Million Giveaway: https://bit.ly/Rexas1M Whitepaper: https://rexas.com/rexas-whitepaper.pdf Twitter/X: https://x.com/rexasfinance Telegram: https://t.me/rexasfinanceCapitals' Alex Ovechkin Out 4-6 Weeks with Fractured Leg Injury amid Gretzky Chase
BIZENGRI ® is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic 1 Merus and Partner Therapeutics announced a license agreement for U.S. commercialization UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics ® and Triclonics ® ), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI ® (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 ( NRG1 ) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI ® has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction. 1 See Important Safety Information below. We believe this approval fills an important need for patients with NRG1 + cancer who have not previously had treatment options approved to specifically target this driver. BIZENGRI ® (zenocutuzumab-zbco) 20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks. “The FDA approval of BIZENGRI ® marks an important milestone for patients with pancreatic adenocarcinoma or NSCLC that is advanced unresectable or metastatic and harbors the NRG1 gene fusion. I have seen firsthand how treatment with BIZENGRI ® can deliver clinically meaningful outcomes for patients,” said Alison Schram, MD, an attending medical oncologist in the Early Drug Development Service at Memorial Sloan Kettering Cancer Center and a principal investigator for the ongoing eNRGy trial. “I am extraordinarily grateful for the patients and families who participated in the trial.” “BIZENGRI ® is Merus’s first approved medicine based on our highly innovative and proprietary Biclonics ® technology platform and offers significant promise for patients with NRG1 + pancreatic adenocarcinoma and NRG1 + NSCLC,” said Shannon Campbell, Chief Commercial Officer of Merus. “This approval is a testament to both our technology and strong execution as we continue to develop our multispecific platforms and pipeline, including our lead asset petosemtamab.” The approval of BIZENGRI ® is based on data from the eNRGy trial, a multicenter, open-label clinical trial that enrolled patients with NRG1 + pancreatic adenocarcinoma or NRG1 + NSCLC that is advanced unresectable or metastatic and had disease progression on or after prior systemic therapy. In patients with NRG1 + pancreatic adenocarcinoma (n=30), BIZENGRI ® demonstrated an ORR of 40% (95% CI, 23%-59%). DOR in NRG1 + pancreatic adenocarcinoma ranged from 3.7 months to 16.6 months. In the same trial, patients with NRG1 + NSCLC (n=64) who were treated with BIZENGRI ® demonstrated an ORR of 33% (95% CI, 22%-46%). The median DOR in NRG1 + NSCLC was 7.4 months (95% CI, 4.0-16.6). Response rates were measured using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR). In the pooled safety population (N=175), the most common (≥10%) adverse reactions were diarrhea, musculoskeletal pain, fatigue, nausea, infusion-related reactions (IRR), dyspnea, rash, constipation, vomiting, abdominal pain, and edema. The most common Grade 3 or 4 laboratory abnormalities (≥2%) were increased gamma-glutamyltransferase, decreased hemoglobin, decreased sodium, decreased platelets, increased aspartate aminotransferase, increased alanine aminotransferase, increased alkaline phosphatase, decreased magnesium, decreased phosphate, increased activated partial thromboplastin time, and increased bilirubin. “The Personalized Medicine Coalition applauds the approval of BIZENGRI ® , a new targeted therapy for NRG1 + pancreatic adenocarcinoma and NRG1 + NSCLC that are advanced unresectable or metastatic,” said Edward Abrahams, President of the Washington-based education and advocacy organization. “In keeping with the growing number of personalized medicines on the market today, BIZENGRI ® offers the only approved NRG1 + therapy for patients with these difficult-to-treat cancers.” The company plans to help appropriate patients gain access to BIZENGRI ® by providing resources and support based on each patient's needs and situation. PTx AssistTM is available to help guide patients through treatment, from providing educational information to helping to understand insurance coverage and identifying potential financial assistance options. For more information, patients and providers can call 1-844-637-8777, Monday through Friday, from 8:00 a.m. to 8:00 p.m. ET. Please see full Prescribing Information, including Boxed WARNING, at www.BIZENGRI.com/pi . About BIZENGRI ® BIZENGRI ® is a bispecific antibody that binds to the extracellular domains of HER2 and HER3 expressed on the surface of cells, including tumor cells, inhibiting HER2:HER3 dimerization and preventing NRG1 binding to HER3 . BIZENGRI ® decreased cell proliferation and signaling through the phosphoinositide 3-kinase-AKT-mammalian target of rapamycin pathway. In addition, BIZENGRI ® mediates antibody-dependent cellular cytotoxicity. BIZENGRI ® showed antitumor activity in mouse models of NRG1 + lung and pancreatic cancers. 1 About the eNRGy Trial The eNRGy trial (Clinicaltrials.gov NCT02912949) is a multicenter, open-label clinical trial that includes patients with advanced unresectable or metastatic NRG1 + pancreatic adenocarcinoma or NRG1 + NSCLC who have disease progression on or after prior systemic therapy. There were 30 patients in the NRG1 + pancreatic adenocarcinoma group and 64 patients in the NRG1 + NSCLC group. The main outcome measures were ORR and DOR, as determined by BICR according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. 1 In the NRG1+ pancreatic adenocarcinoma group, the median age was 49 years (range, 21-72 years); 43% were female; 87% were White, 7% were Asian, and 3.3% were Black or African American. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and all patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range, 0-5); 97% had prior systemic therapy with prior chemotherapy. 1 In the NRG1+ NSCLC group, the median age was 64 years (range, 32-86 years); 64% were female, 33% were White, 56% were Asian, and 3.4% were Black or African American. ECOG performance status was 0 or 1 in 97% of patients or 2 in 3% of patients, and 98% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range, 1-6). 1 IMPORTANT SAFETY INFORMATION BOXED WARNING: EMBRYO-FETAL TOXICITY Embryo-Fetal Toxicity: Exposure to BIZENGRI ® during pregnancy can cause embryo-fetal harm. Advise patients of this risk and the need for effective contraception. WARNINGS AND PRECAUTIONS Infusion-Related Reactions/Hypersensitivity/Anaphylactic Reactions BIZENGRI ® can cause serious and life-threatening infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions. Signs and symptoms of IRR may include chills, nausea, fever, and cough. In the eNRGy study, 13% of patients experienced IRRs, all were Grade 1 or 2; 91% occurred during the first infusion. Administer BIZENGRI ® in a setting with emergency resuscitation equipment and staff who are trained to monitor for IRRs and to administer emergency medications. Monitor patients closely for signs and symptoms of infusion reactions during infusion and for at least 1 hour following completion of first BIZENGRI ® infusion and as clinically indicated. Interrupt BIZENGRI ® infusion in patients with ≤ Grade 3 IRRs and administer symptomatic treatment as needed. Resume infusion at a reduced rate after resolution of symptoms. Immediately stop the infusion and permanently discontinue BIZENGRI ® for Grade 4 or life-threatening IRR or hypersensitivity/anaphylaxis reactions. Interstitial Lung Disease/Pneumonitis BIZENGRI ® can cause serious and life-threatening interstitial lung disease (ILD)/pneumonitis. In the eNRGy study, ILD/pneumonitis occurred in 2 (1.1%) patients treated with BIZENGRI ® . Grade 2 ILD/pneumonitis (Grade 2) resulting in permanent discontinuation of BIZENGRI ® occurred in 1 (0.6%) patient. Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold BIZENGRI ® in patients with suspected ILD/pneumonitis and administer corticosteroids as clinically indicated. Permanently discontinue BIZENGRI ® if ILD/pneumonitis ≥ Grade 2 is confirmed. Left Ventricular Dysfunction BIZENGRI ® can cause left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including BIZENGRI ® . Treatment with BIZENGRI ® has not been studied in patients with a history of clinically significant cardiac disease or LVEF less than 50% prior to initiation of treatment. In the eNRGy study, Grade 2 LVEF decrease (40%-50%; 10 - 19% drop from baseline) occurred in 2% of evaluable patients. Cardiac failure without LVEF decrease occurred in 1.7% of patients, including 1 (0.6%) fatal event. Before initiating BIZENGRI ® , evaluate LVEF and monitor at regular intervals during treatment as clinically indicated. For LVEF of less than 45% or less than 50% with absolute decrease from baseline of 10% or greater which is confirmed, or in patients with symptomatic congestive heart failure (CHF), permanently discontinue BIZENGRI ® . Embryo-Fetal Toxicity Based on its mechanism of action, BIZENGRI ® can cause fetal harm when administered to a pregnant woman. No animal reproduction studies were conducted with BIZENGRI ® . In postmarketing reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios manifesting as fatal pulmonary hypoplasia, skeletal abnormalities, and neonatal death. In animal models, studies have demonstrated that inhibition of HER2 and/or HER3 results in impaired embryo-fetal development, including effects on cardiac, vascular and neuronal development, and embryolethality. Advise patients of the potential risk to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of BIZENGRI ® . Advise females of reproductive potential to use effective contraception during treatment with BIZENGRI ® and for 2 months after the last dose. ADVERSE REACTIONS NRG1 Gene Fusion Positive Unresectable or Metastatic Pancreatic Adenocarcinoma Serious adverse reactions occurred in 23% of patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma who received BIZENGRI ® . There were 2 fatal adverse reactions, one due to COVID-19 and one due to respiratory failure. In patients with NRG1 Gene Fusion Positive Pancreatic Adenocarcinoma who received BIZENGRI ® the most common (≥20%) adverse reactions, including laboratory abnormalities, were increased alanine aminotransferase (51%), diarrhea (36%), increased aspartate aminotransferase (31%), increased bilirubin (31%), decreased phosphate (31%), increased alkaline phosphatase (28%), decreased sodium (28%) musculoskeletal pain (28%), decreased albumin (26%), decreased potassium (26%), decreased platelets (26%), decreased magnesium (24%), increased gamma-glutamyl transpeptidase (23%), decreased hemoglobin (23%), vomiting (23%), nausea (23%), decreased leukocytes (21%), and fatigue (21%). NRG1 Gene Fusion Positive Unresectable or Metastatic NSCLC Serious adverse reactions occurred in 25% of patients with NRG1 Gene Fusion Positive NSCLC who received BIZENGRI ® . Serious adverse reactions in ≥ 2% of patients included pneumonia (n=4) dyspnea and fatigue (n=2 each). Fatal adverse reactions occurred in 3 (3%) patients and included respiratory failure (n=2), and cardiac failure (n=1). Permanent discontinuation of BIZENGRI ® due to an adverse reaction occurred in 3% of patients. Adverse reactions resulting in permanent discontinuation of BIZENGRI ® included dyspnea, pneumonitis and sepsis (n=1 each). In patients with NRG1 Gene Fusion Positive NSCLC who received BIZENGRI ® , the most common (>20%) Adverse Reactions, including laboratory abnormalities, were decreased hemoglobin (35%), increased alanine aminotransferase (30%), decreased magnesium (28%), increased alkaline phosphatase (27%), decreased phosphate (26%) diarrhea (25%), musculoskeletal pain (23%), increased gamma-glutamyl transpeptidase (23%), increased aspartate aminotransferase (22%), and decreased potassium (21%). Please see full Prescribing Information, including Boxed WARNING, at BIZENGRI.com/pi. About Merus N.V. Merus is a clinical stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ® . Multiclonics ® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website https://merus.nl and LinkedIn . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding product development and the potential benefits and treatment impact of BIZENGRI ® (zenocutuzumab-zbco); our belief that this approval fills an important need for patients with NRG1 + cancer who have not previously had treatment options approved to specifically target this driver; the expectation of BIZENGRI ® to be available to patients in the coming weeks; the promise BIZENGRI® holds for patients with NRG1 + pancreatic adenocarcinoma and NSCLC; its implication to our technology and execution as we continue to develop our multispecific platforms and pipeline, including our lead asset petosemtamab; and our expectation to provide patients with access to BIZENGRI ® , as well as offering helpful resources and support based on each patient's needs and situation. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Merus. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or antibody candidates; potential issues associated with regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; our reliance on third parties to conduct our clinical trials, and the potential for those third parties to not perform satisfactorily; impacts of the volatility in the global economy, including global instability, including the ongoing conflicts in Europe and the Middle East; we may not identify suitable Biclonics ® or bispecific antibody candidates under our collaborations, or our collaborators may fail to perform adequately under our collaborations; our reliance on third parties to manufacture our product candidates, which may delay, prevent, or impair our development and commercialization efforts; protection of our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors, and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed with the Securities and Exchange Commission, or SEC, on October 31, 2024, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Multiclonics ® , Biclonics ® , Triclonics ® , and BIZENGRI ® are registered trademarks of Merus N.V. Reference: 1. BIZENGRI. Prescribing information. Merus N.V.; 2024. ©2024 Merus N.V. All rights reserved. MAT-0247 V4 12/24
RumbleOn Announces Commencement of $10.0 Million Fully Backstopped Registered Rights Offering